6533b7ddfe1ef96bd1274931

RESEARCH PRODUCT

A phase I/II multicentric trial of gemcitabine and epirubicin in patients with advanced pancreatic carcinoma

J F RiemannW MartinJ. C. EickhoffPeter R. GalleDirk HartmannR JakobsM MöhlerA Eickhoff

subject

OncologyAdultMaleCancer Researchmedicine.medical_specialtyPancreatic diseaseendocrine system diseasesmedicine.drug_classmedicine.medical_treatmentpancreatic cancerAntineoplastic AgentschemotherapyAntimetaboliteDeoxycytidinechemistry.chemical_compoundHemoglobinsLeukocyte CountInternal medicinePancreatic cancerClinical StudiesmedicineHumansIn patientAgedNeoplasm StagingChemotherapyDose-Response Relationship Drugbusiness.industryPlatelet CountgemcitabineMiddle Agedmedicine.diseaseepirubicinGemcitabineSurgeryPancreatic NeoplasmsOncologychemistryDeoxycytidineFemalebusinessEpirubicinmedicine.drug

description

Potential synergistic interaction between gemcitabine (GEM) and epirubicin (EPI) in pancreatic cancer have been described previously. The maximum-tolerated dose in this trial was GEM 1000 mg m(-2) and EPI 45 mg m(-2). Median time to progression was 5.1 months and median survival time 7.4 months. This combination appears well tolerated and shows promising clinical activity.

yearjournalcountryeditionlanguage
2006-05-01British Journal of Cancer
10.1038/sj.bjc.6603174http://europepmc.org/articles/PMC2361302